- N Engl J Med 2022; 386:1668-1669
Data were pooled from 36 patients who received the anti–CTLA-4 antibody ipilimumab after metastatic melanoma progression during therapy with nivolumab (anti–PD-1) plus relatlimab (anti–LAG-3) to assess whether immunotherapies that target distinct checkpoints have different mechanisms of action. The findings suggest that cross-resistance emerges when tumors progress with immune checkpoint inhibitors.
- N Engl J Med 2022; 386:e28
A 47-year-old woman presented with eyelid itching and the sensation of a foreign body in her right eye. A pigmented mass was observed on the eyelid, and a large, pigmented lesion was observed on the palpebral conjunctiva on eyelid eversion. Excisional biopsy was performed, and a malignant melanoma was detected.
- N Engl J Med 2022; 386:24-34
Two defined immune checkpoints have been exploited for cancer treatment. LAG-3 is a third immune checkpoint that blocks lymphocyte activation. Relatlimab, a monoclonal antibody against LAG-3, interferes with this block. Relatlimab plus nivolumab as compared with nivolumab alone in melanoma produced superior progression-free survival.
- N Engl J Med 2022; 386:91-92
With combination immunotherapy, the 5-year survival of patients with advanced melanoma is now approximately 50%. Outcomes can still be further improved, and evaluating new immune checkpoint targets is an attractive possibility. Patients with advanced melanoma have a reduced immune response to tumors, owing to an elevated expression of inhibitory receptors...
- N Engl J Med 2021; 385:1196-1206
Metastatic uveal melanoma is an aggressive disease without an established standard treatment. In a randomized trial that evaluated tebentafusp, a soluble T-cell receptor bispecific protein, overall survival at 1 year was 73% among patients who received tebentafusp, as compared with 59% among those who received the investigator’s choice of therapy.
- N Engl J Med 2021; 384:2229-2240
The incidence of melanoma has increased, but mortality has declined with improved management. Sentinel-node sampling has reduced morbidity associated with staging surgery, and treatment of advanced disease has improved with the use of targeted therapy and checkpoint immunotherapy.
- N Engl J Med 2021; 384:72-79
The incidence of melanoma of the skin is 6 times as high as it was 40 years ago; mortality has stayed low. UV light exposure is the strongest environmental risk factor, but its magnitude gives a relative risk of about 2. The most likely factors influencing the increase are changing...
- N Engl J Med 2020; 383:1139-1148
At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with BRAF V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo.
- N Engl J Med 2020; 383:169-169
A 47-year old man presented with numerous pigmented lesions on the nail beds, penis, and oral mucosa. Biopsy confirmed a diagnosis of mucosal and ungual melanoma metastases.
- N Engl J Med 2020; 382:2573-2574
A patient with severe autoimmune pneumonitis from immune checkpoint inhibitor therapy for metastatic melanoma had improved clinical and radiographic clearance of the pneumonitis associated with treatment with inhaled vasoactive intestinal peptide.
- N Engl J Med 2020; 382:e90
A 59-year-old man with metastatic colon cancer presented with pink, firm skin lesions around his abdominal surgical scar. A biopsy showed cutaneous metastases.
- N Engl J Med 2020; 382:e7
An 85-year-old man presented with a 2-week history of passing dark stools. Endoscopy revealed multiple polypoid nodules, and a diagnosis of metastatic melanoma was made.
- N Engl J Med 2019; 381:1535-1546
With a 5-year minimum follow-up in patients with metastatic melanoma, overall survival at 5 years was 52% with a combination of nivolumab plus ipilimumab, as compared with 44% with nivolumab alone and 26% with ipilimumab alone. Programmed cell death ligand 1 expression did not influence the response rate or progression-free...
- N Engl J Med 2019; 381:1458-1458
A 37-year-old man presented to the dermatology clinic with two types of skin lesion. Two types of nevi, both with the same HRAS mutation, were observed in biopsy specimens. A diagnosis of phakomatosis pigmentokeratotica was made.
- N Engl J Med 2019; 381:626-636
In long-term follow-up of more than 500 patients with melanoma containing a BRAF V600E or V600K mutation, a combination of dabrafenib plus trametinib was associated with progression-free survival in 19% of the patients and overall survival in 34% at 5 years. A complete response to dabrafenib plus trametinib...